Related Experiment Videos
Rapid detection assays for multidrug resistance.
Arzneimittel-Forschung
|December 1, 1988
Summary
This study developed rapid assays to detect multidrug resistance (MDR) in cancer cells. Assays measuring doxorubicin incorporation and rhodamine 123 accumulation effectively identified MDR cells.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Multidrug resistance (MDR) in cancer poses a significant challenge to chemotherapy efficacy.
- Developing rapid and simple assays for MDR detection is crucial for effective treatment strategies.
- Investigated cell lines include doxorubicin-resistant S180 (S180DOX), colchicine-resistant CHO (CHOCOL), and cytarabine-resistant L1210 (L1210AraC).
Purpose of the Study:
- To develop and evaluate simple, rapid assays for the detection of multidrug resistance (MDR).
- To assess the utility of two distinct assays in identifying MDR cancer cell lines.
Main Methods:
- Assay 1: Measured the inhibition of radioactive nucleic acid precursor incorporation into tumor cells upon doxorubicin treatment.
- Assay 2: Analyzed the intracellular accumulation of the fluorescent dye rhodamine 123 (R123) in different cell lines.
- Compared R123 accumulation kinetics in MDR (S180DOX, CHOCOL) and non-MDR (L1210AraC) cell lines.
Main Results:
- Resistant S180DOX and CHOCOL cells demonstrated significantly slower R123 accumulation compared to sensitive parental lines and L1210AraC cells.
- The doxorubicin incorporation assay showed differential responses between resistant and sensitive cell lines.
- Both evaluated assays proved capable of distinguishing MDR phenotypes.
Conclusions:
- The developed short-term assays are effective tools for the rapid detection of multidrug resistance (MDR).
- These assays can aid in identifying cancer cells with MDR phenotypes, potentially guiding personalized treatment decisions.